• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
【24h】

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.

机译：基因定向酶/前体药物治疗癌症:历史评价和未来prospectives。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gene therapy of cancer is a novel approach with the potential to selectively eradicate tumour cells, whilst sparing normal tissue from damage. In particular, gene-directed enzyme prodrug therapy (GDEPT) is based on the delivery of a gene that encodes an enzyme which is non-toxic per se, but is able to convert a prodrug into a potent cytotoxin. Several GDEPT systems have been investigated so far, demonstrating effectiveness in both tissue culture and animal models. Based on these encouraging results, phase I/II clinical trials have been performed and are still ongoing. The aim of this review is to summarise the progress made in the design and application of GDEPT strategies. The most widely used enzyme/prodrug combinations already in clinical trials (e.g., herpes simplex 1 virus thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine), as well as novel approaches (carboxypeptidase G2/CMDA, horseradish peroxidase/indole-3-acetic acid) are described, with a particular attention to translational research and early clinical results. Copyright 2001 Wiley-Liss, Inc.
机译：癌症基因治疗是一种新颖的方法有选择地消灭肿瘤的潜力细胞,同时避免正常组织损伤。特别是,gene-directed酶前体药物治疗(GDEPT)是基于交货的无毒基因编码一种酶本身,而是能够将一个前药转换成强大的细胞毒素。到目前为止,调查证明有效性组织培养和动物模型。在这些令人鼓舞的结果,I / II期临床试验已经执行,仍在继续。本文的目的是总结设计和应用的进展GDEPT策略。已经在临床酶/前体药物组合试验(如1单纯疱疹病毒胸腺嘧啶核苷激酶/更昔洛韦和胞嘧啶脱氨酶/ 5-fluorocytosine),以及小说方法(羧肽酶G2 / CMDA,辣根过氧化物酶/ indole-3-acetic酸),特别注意转化研究和早期临床结果。2001 Wiley-Liss, Inc。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号